294
Participants
Start Date
August 12, 2014
Primary Completion Date
August 31, 2017
Study Completion Date
December 27, 2022
Nivolumab
Specified dose on specified days
Doxorubicin
Specified dose on specified days
Vinblastine
Specified dose on specified days
Dacarbazine
Specified dose on specified days
Local Institution - 0031, Vienna
Local Institution - 0014, B-leuven
Local Institution - 0032, Innsbruck
Local Institution - 0015, Ghent
Local Institution - 0022, Hospitalet Llobregat- Barcelona
Local Institution - 0005, New York
Local Institution - 0037, Berlin
Local Institution - 0006, Allentown
Local Institution - 0035, Rozzano (milano)
Local Institution - 0036, Hamburg
Local Institution - 0027, Majadahonda - Madrid
Local Institution - 0023, Marbella
Local Institution - 0001, Atlanta
Local Institution - 0019, Bologna
Local Institution - 0008, Detroit
Local Institution - 0033, Cologne
Local Institution - 0003, Rochester
Local Institution - 0007, Houston
Local Institution - 0020, Napoli
Local Institution - 0034, Ulm
Local Institution - 0030, Los Angeles
Local Institution - 0009, Los Angeles
Local Institution - 0002, Boston
Local Institution - 0025, Boston
Local Institution - 0041, Boston
Local Institution - 0047, Hackensack
Local Institution - 0040, Basking Ridge
Local Institution - 0004, Nashville
Local Institution - 0046, Vancouver
Local Institution - 0042, Toronto
Local Institution - 0044, Prague
Local Institution - 0016, Amsterdam
Local Institution - 0038, Groningen
Local Institution - 0017, Utrecht
Local Institution - 0043, Swansea
Local Institution - 0012, Withington
Local Institution - 0026, Oxford
Local Institution - 0013, Sutton
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY